Log In
BCIQ
Print this Print this
 

ANN-004

  Manage Alerts
Collapse Summary General Information
Company Weill Cornell Medical College
DescriptionAAV to treat severe allergies
Molecular Target
Mechanism of Action 
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard IndicationAllergy
Indication DetailsTreat severe allergies
Regulatory Designation
PartnerAdverum Biotechnologies Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$105.6M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/12/2016

$105.6M

0

0

Get a free BioCentury trial today